|Articles|May 23, 2016

Determining the proper intracameral moxifloxacin dosage

Steve Arshinoff, MD, FRCSC, of the University of Toronto, outlines the proper dosage and administration technique for intracameral moxifloxacin during cataract surgery.

How to determine the proper dosage for intracameral moxifloxacin

Steve Arshinoff, MD, FRCSC, of the University of Toronto, outlines the proper dosage and administration technique for intracameral moxifloxacin during cataract surgery.

Want more? Check out these related articles:

Intracanalicular drug depot may fill unmet need for better topical therapy

Combination of NSAIDs and steroids reduces CME outcomes

How new ‘evolving’ IOL formula maximizes lens accuracy

Viscosplit and crack in mini-coaxial small-incision cataract surgery

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Determining the proper intracameral moxifloxacin dosage

How to determine the proper dosage for intracameral moxifloxacin

Related Content

FDA guidance to help accelerate cell and gene therapies

The Residency Report: Cardiovascular risk scores as a window into ocular disease

Oculis phase 3 DIAMOND trials miss vision endpoints in diabetic macular edema

TearSolutions advances Lacripep into phase 2 following dual FDA designations in neurotrophic keratitis

Opuviz aflibercept biosimilar launches in Europe for retinal diseases

Latest CME

(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop

(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Retina Updates in Montréal

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Interventional Dry Eye: A Stepwise Treatment & Management Approach

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Trending on Ophthalmology Times - Clinical Insights for Eye Specialists

FDA guidance to help accelerate cell and gene therapies

Oculis phase 3 DIAMOND trials miss vision endpoints in diabetic macular edema

The Residency Report: Cardiovascular risk scores as a window into ocular disease

TearSolutions advances Lacripep into phase 2 following dual FDA designations in neurotrophic keratitis

Outlook Therapeutics resubmits BLA for bevacizumab-vikg (ONS-5010/LYTENAVA)